Nakagawa Miyuki M

Show results for

Metabolomics (3)
Transcriptomics (2)

Organisms

Homo sapiens (2)

Repository

MetaboLights (3)
biostudies-arrayexpress (2)

Technology Type

Mass spectrometry (3)

Instrument Platform

Capillary electrophoresis MS - negative (3)
Capillary electrophoresis MS - positive (3)

Publication Date

2023 (3)
2014 (1)
2009 (1)

CHEBI ID

CHEBI:10049 (3)
CHEBI:10072 (3)
CHEBI:1026 (3)
CHEBI:1148 (3)
CHEBI:1157 (3)
CHEBI:132546 (3)
CHEBI:132958 (3)
CHEBI:134206 (3)
CHEBI:135063 (3)
CHEBI:139328 (3)
CHEBI:14314 (3)
CHEBI:143269 (3)
CHEBI:14336 (3)
CHEBI:1456 (3)
CHEBI:14973 (3)
CHEBI:15318 (3)
CHEBI:15346 (3)
CHEBI:15351 (3)
CHEBI:15354 (3)
CHEBI:15355 (3)
CHEBI:15356 (3)
CHEBI:15380 (3)
CHEBI:15422 (3)
CHEBI:15428 (3)
CHEBI:1547 (3)
CHEBI:15479 (3)
CHEBI:15531 (3)
CHEBI:15551 (3)
CHEBI:15553 (3)
CHEBI:15573 (3)

Metabolite Name

(Methylthio)acetate (2)
1-Aminoethylphosphonate (2)
10-Hydroxydecanoate (2)
2',3'-cCMP (2)
2,3-DPG (2,3-Disphospho-D-glycerate) (2)
2,3-Pyridinedicarboxylate (2)
2,4-Dihydroxypyrimidine-5-carboxylate (2)
2,5-Dihydroxybenzoate (2)
2-Amino-3-phosphonopropionate (2)
2-Aminoethylphosphonate (2)
2-Deoxyglucose 6-phosphate (2)
2-Deoxyribose 1-phosphate (2)
2-Furoate (2)
2-Hydroxy-4-methylpentanoate (2)
2-Hydroxybutyrate (2)
2-Hydroxyglutarate (2)
2-Hydroxyisobutyrate (2)
2-Hydroxyoctanoate (2)
2-Hydroxypentanoate (2)
2-Hydroxyphenylacetate (2)
2-Isopropylmalate (2)
2-Oxoadipate (2)
2-Oxobutyrate (2)
2-Oxoglutarate (2)
2-Oxoisopentanoate (2)
2-Oxooctanoate (2)
2-Quinolinecarboxylate (2)
2-Thiopheneacetate (2)
2PG (D-Glycerate 2-phosphate) (2)
3',5'-Cyclic dAMP (2)

Study type

Comparative genomic hybridization by array (1)
Transcription profiling by array (1)

Release Date

2014 (1)
2009 (1)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Cell NAMPTi treatment)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7251 | MetaboLights

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAMPT targeted therapy)

2023-10-10 | MTBLS7252 | MetaboLights

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAD targeted time-course)

2023-10-10 | MTBLS7253 | MetaboLights

Genomic alterations of 332 malignant lymphoma using BAC array CGH analysis

Clonal heterogeneity in lymphoid malignancies has been recently reported in adult T-Cell lymphoma/leukemia, peripheral T-cell lymphoma, not otherwise specified, and mantle cell lymphoma (MCL). Our analysis was extended to other types of lymphoma including marginal zone lymphoma, follicular lymphom...

ORGANISM(S): Homo sapiens

2014-04-01 | E-GEOD-54303 | biostudies-arrayexpress

Expression defined classification of subtypes of diffuse large B cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) comprises molecularly distinct subgroups such as activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCLs. We previously reported that CD5(+) and CD5(-)CD10(+) DLBCL constitute clinically relevant subgroups. To determine whether these 2 subgroups...